GPC Biotech is a German biopharmaceutical company that discovers and develops anticancer drugs. The company’s product portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer. In March 2000, the company acquired Mitotix, Inc., an American drug discovery and development company focused on treatments for cancer and fungal infections. GPC Biotech was founded in 1997 and currently operates as a subsidiary of Agennix AG.

NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.

We are a clinical oncology company with the ability to identify compounds for the treatment of new cancer indications with limited therapeutic options. We have identified satraplatin as having a significant effect in haemato-oncology indications and are developing it as a precision platinum for orphan lymphomas. We are scaling up the process of identifying and developing clinical compounds using proprietary oncologist know-how amplified by AI and data mining to systematically pursue high-yield candidates for cancer indications of large unmet medical need.

Nerium Biotechnology, Inc., a biotechnology company, engages in the development of oleander-based products for the treatment of certain forms of proliferative diseases and viral infections. Its lead product includes Anvirzel, which is used to treat various forms of cancer. The company’s product line also comprises HIviral for the treatment of HIV/AIDS; HEP-viral for the treatment of hepatitis C; and NeriumAD, a skin cream for age-defying treatment. Nerium Biotechnology, Inc. is based in San Antonio, the United States.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas.

Jinan Jifu Pharmaceutical Technology Co., Ltd., established on 2008-03-26, The scope of business includes the development of medical technology,technology transfer,Technical Advisory Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kunming Institute of Precious Metals is a Chinese private company located in Kunming. The firm engages in scientific research institute that specializing in the development of precious metals.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Jinan Kangquan Pharmaceutical Technology Co., Ltd., established on 2005-04-14, Business scope includes licensed business items:none;General operating items:Development of medical technology,transfer,technical consulting.(Except for projects that have not obtained special permits)

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Neijiang Lobel Material Technology Co., Ltd., established on 2015-06-02, Business scope includes new material research and experimental development;precious metal(gold,platinum,Palladium,ruthenium,silver)Powder and conductive paste manufacturing;Manufacture of precious metal products for industrial or laboratory use;Sell ​​metal materials;Sales of special instruments;sell minerals(Free of Hazardous Chemicals);sell electronics;Sales of chemical products(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Kunming Guiyan Pharmaceutical Co., Ltd., established on 2004-06-29, Business scope includes licensed projects:pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Non-ferrous metal alloy sales;Import and export;Technology Import and Export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).